# Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

> **NCT00179647** · PHASE3 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 1913 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** lenalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00179647
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-12
- **Final completion:** 2009-04
- **Target enrollment:** 1913 (ACTUAL)
- **Last updated:** 2010-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179647, "Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00179647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*